Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Immerge BioTherapeutics announces identification of PERV receptor

27.05.2003


Important step forward for safety of xenotransplantation



This week in the Proceedings of the National Academy of Sciences, researchers from Immerge BioTherapeutics, Inc., announced that they have identified the receptors that are used by porcine endogenous retrovirus (PERV) in order to enter and infect a cell (PNAS; May 27, 2003; vol. 100, no. 11; 6759-6764). This is a critical discovery because it allows scientists to begin to develop strategies to prevent PERV replication. PERV has been considered a key safety issue in the development of xenotransplantation using pig organs because the virus has shown the ability to infect some human cells in laboratory tissue cultures. The study was performed in a collaborative effort between Immerge and the academic groups of Professors Robin Weiss, University College, London, UK and Daniel Salomon, The Scripps Research Institute, La Jolla, CA.

"Our identification of the PERV receptor is a major step forward because it allows us to address fundamental aspects of the biology of this virus," said Dr Clive Patience, Director of the Safety Program at Immerge. "For instance, PERV has grown in only three of approximately 40 human cell lines that we and others have tested. To date, we have not understood why most human cells do not support PERV growth. We can now begin to address this type of fundamental issue."


PERV is a virus that all pigs are born with, which poses no harm to the pig itself. However, unlike other viruses, which can be eliminated either through breeding or raising pigs in a clean lab environment, multiple copies of PERV form part of the normal genomic DNA of pigs and are therefore passed from one generation to the next.

"PERV is of concern in developing xenotransplantation of porcine organs towards an accepted procedure in clinical medicine," commented Professor Robin Weiss from University College, London. "We need to understand the basic virology of PERV, and indeed other porcine microorganisms, before xenotransplantation can be considered a safe procedure."

There is a critical need to identify new sources of organs for the growing number of people needing life-saving transplants around the world. In the U.S. alone, there are more than 81,000 people on the waiting list for organs and an unknown number of additional people needing organs who did not qualify for the transplant list because of age, illness or other issues.

"There is an unmet need in clinical transplantation for donors, and the availability of acceptable porcine organs could solve this huge demand" said Professor Dan Salomon from The Scripps Research Institute. "It remains important to identify the risk of a potentially infectious agent to both the patient receiving a transplant as well as others. Our identification of the PERV receptors will allow us to begin to address this issue."

As part of its progress toward clinical xenotransplantation, Immerge BioTherapeutics Inc. has developed a safety program with a number of international expert collaborators. The depth of Immerge’s safety program is unique among companies conducting xenotransplantation research. The company has previously reported the identification of animals within its miniature swine herd that do not transmit PERV to human cell lines (Oldmixon et al. Journal of Virology 2002; 76: 3045-3048). In the past year, in collaborative efforts with the University of Missouri-Columbia and Infigen, Inc., Immerge also announced the birth of cloned, double knock-out miniature swine that lack expression of the GGTA1 gene. This gene is responsible for rapid rejection of organs and makes the animal organs more compatible for potential human transplant.


Immerge BioTherapeutics was formed on September 26, 2000, as a joint venture between Novartis Pharma AG and BioTransplant Incorporated. The company, which began operations on January 2, 2001, focuses its research efforts toward developing therapeutic applications for xenotransplantation.

Susan Hayes | EurekAlert!

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

Bodyguards in the gut have a chemical weapon

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>